M
Marijke van den Berg
Researcher at Utrecht University
Publications - 15
Citations - 1365
Marijke van den Berg is an academic researcher from Utrecht University. The author has contributed to research in topics: Haemophilia & Whole blood. The author has an hindex of 9, co-authored 15 publications receiving 1245 citations.
Papers
More filters
Journal ArticleDOI
Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study
Christoph Male,Nadine G. Andersson,Anne Rafowicz,Ri Liesner,Karin Kurnik,Krista Fischer,Helen Platokouki,Elena Santagostino,Hervé Chambost,Beatrice Nolan,Christoph Königs,Gili Kenet,Rolf Ljung,Marijke van den Berg +13 more
TL;DR: Nonsense mutations and large deletions were strongly associated with the risk of inhibitor development and were associated with an inhibitor risk of 26.9% and 33.3% in an unselected, well-defined cohort of PUP with SHB.
Journal ArticleDOI
Cost effectiveness of haemophilia treatment: a cross-national assessment
Barbara Lippert,Karin Berger,Erik Berntorp,Paul L. F. Giangrande,Marijke van den Berg,Wolfgang Schramm,Uwe Siebert +6 more
TL;DR: The use of prophylactic treatment was overall more effective than on-demand therapy in young haemophiliacs, but at extremely high cost.
Journal ArticleDOI
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Peter Volkers,Kay Martin Hanschmann,Thierry Calvez,Hervé Chambost,Peter William Collins,Virginie Demiguel,Daniel P. Hart,Charles R. M. Hay,Jenny Goudemand,Rolf Ljung,Ben Palmer,Elena Santagostino,Ella M. van Hardeveld,Marijke van den Berg,Brigitte Keller-Stanislawski +14 more
TL;DR: Standard treatment of congenital haemophilia A is based on replacement therapy with coagulation factor VIII (FVIII) products, but a major complication of FVIII therapy is the occurrence of IgG alloantibodies (inhibitors) that neutralize FV III activity.
Journal ArticleDOI
Summary report of the First International Conference on inhibitors in haemophilia A.
Sébastien Lacroix-Desmazes,David W Scott,Jenny Goudemand,Marijke van den Berg,Michael Makris,Alice S. van Velzen,Elena Santagostino,David Lillicrap,Frits R. Rosendaal,Anneliese Hilger,Zuben E. Sauna,Johannes Oldenburg,Lorenzo G. Mantovani,M Elisa Mancuso,Craig M. Kessler,Charles R. M. Hay,Paul Knoebl,Giovanni Di Minno,Keith Hoots,Amanda Bok,M. Brooker,Erica Buoso,Pier Mannuccio Mannucci,Flora Peyvandi +23 more
TL;DR: The First International Conference on Inhibitors in Haemophilia A was held on 4–5 March, 2016 and the major theme was the development of factor VIII (FVIII) inhibitors, which occurs in 30–35% of previously untreated children infused with the available commercial products.
Journal ArticleDOI
The Fourth Annual Meeting of the International Network for Pediatric Hemophilia: Current Challenges and Recommendations in the Clinical Care of Children with Hemophilia.
TL;DR: The International Network for Pediatric Hemophilia (INPH) comprises a group of physicians committed to the unique care of and challenges facing pediatric hemophilia patients by collaborating on an international level.